Search results
22 cze 2023 · Berlin, June 22, 2023 – Bayer announced today the initiation of FINE-ONE, a global, multicenter, randomized, placebo-controlled, double blind parallel-group Phase III study to evaluate the efficacy and safety of finerenone versus placebo in adults with chronic kidney disease (CKD) and type 1 diabetes (T1D). The primary objective of the study ...
2 wrz 2022 · Berlin, September 2, 2022 – Bayer announced today that it received approval from the U.S. Food and Drug Administration (FDA) for a label update for Kerendia™ (finerenone) to include findings from the Phase III FIGARO-DKD cardiovascular (CV) outcomes study in patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).
3 dni temu · Berlin, September 27, 2024 – Bayer announced today that new subgroup analyses from the Phase III FINEARTS-HF trial evaluating finerenone (Kerendia™) in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ≥ 40% will be presented at the Heart Failure Society of America (HFSA) Annual Meeting 2024.. Data being presented at HFSA include:
20 wrz 2024 · • Finerenone is the first non-steroidal mineralocorticoid receptor (MR) antagonist to demonstrate definitive benefits in its primary composite endpoint versus placebo in a Phase III study in adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ≥40%, i.e. mildly reduced or preserved LVEF1 • Finerenone showed a 16% relative rate reduction (absolute ...
5 sie 2024 · Finerenone (Kerendia), a nonsteroidal, selective mineralocorticoid receptor antagonist (nsMRA) can reduce the composite of cardiovascular death and total heart failure events in patients with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF), according to topline results from FINEARTS-HF. The randomized trial is the first to show a ...
2 wrz 2024 · Per Bayer, finerenone is the first MR antagonist to demonstrate definitive cardiovascular benefits in a phase III study in patients with this common form of heart failure.
31 sie 2023 · WHIPPANY, N.J.-- (BUSINESS WIRE)-- Bayer’s Kerendia ® (finerenone) was included in the European Society of Cardiology’s (ESC) latest clinical guidance for patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).
